{"schema_version":"secwatch.filing_event.v1","accession":"0000320017-23-000027","form_type":"8-K","ticker":"LSTA","cik":"0000320017","company_name":"LISATA THERAPEUTICS, INC.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.786505+00:00","generated_at":"2026-06-15T10:39:00.277526+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lisata Q1 net loss $6.2M; cash $61.1M; LSTA1 advances but LSTA201 disappoints","bullets":["Q1 net loss $6.2M vs $4.2M YoY; R&D $3.2M, G&A $3.7M.","Cash, equivalents & marketable securities $61.1M as of Mar 31; plus $2.2M non-dilutive NJ tax credit received Q2.","LSTA1: first patient dosed in iLSTA trial for pancreatic cancer; basket trial in solid tumors planned before end of Q2 2023.","LSTA201 for diabetic kidney disease showed safety but no consistent kidney function improvement; development only with partner.","HONEDRA (LSTA12) for critical limb ischemia in Japan: pre-consultation with PMDA; seeking partner."],"urls":{"canonical":"https://secwatch.observer/filing/0000320017-23-000027","json":"https://secwatch.observer/filing/0000320017-23-000027.json","markdown":"https://secwatch.observer/filing/0000320017-23-000027.md","text":"https://secwatch.observer/filing/0000320017-23-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/320017/000032001723000027/0000320017-23-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/320017/000032001723000027/clbs-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T10:39:00.277526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"48cbbc7a48339612d5f4f468ca83c63010991d64","claim":"LISATA THERAPEUTICS, INC. reported financial results for the three months ended March 31, 2023.","evidence_excerpt":"Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/320017/000032001723000027/0000320017-23-000027-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}